CytoDyn Cash Flow Statement

Financials in millions USD. Fiscal year is June - May.

Millions USD. Fiscal year is Jun - May.

Year	2023	2022	2021	2020	2019	2018 - 2004
Net Income	-79.82	-288.16	-174.02	-141.78	-56.19	Upgrade
Depreciation & Amortization	0.18	0.78	1.8	2.03	1.25	Upgrade
Share-Based Compensation	4.28	6.24	10.43	6.55	3.39	Upgrade
Other Operating Activities	50.26	203.42	44.22	64.4	1.09	Upgrade
Operating Cash Flow	-25.11	-77.72	-117.57	-68.8	-50.47	Upgrade
Capital Expenditures	0	0	-0.12	-0.04	-0.05	Upgrade
Investing Cash Flow	0	0	-0.12	-0.04	-0.05	Upgrade
Dividends Paid	0	0	-0.24	0	0	Upgrade
Common Stock Issued	29.03	41.2	1	12.67	38.27	Upgrade
Share Repurchases	0	0	138.33	-0.01	0	Upgrade
Other Financing Activities	0.9	6.82	274.92	67	14.48	Upgrade
Financing Cash Flow	29.93	48.01	137.35	79.67	52.75	Upgrade
Net Cash Flow	4.82	-29.71	19.65	10.83	2.24	Upgrade
Free Cash Flow	-25.11	-77.72	-117.7	-68.84	-50.51	Upgrade
Free Cash Flow Margin	-	-29219.17%	-	-	-	Upgrade
Free Cash Flow Per Share	-0.03	-0.11	-0.20	-0.16	-0.19	Upgrade

Sources: The data provider is Financial Modeling Prep and the numbers are sourced from SEC filings.